SCHEMBL15440706

SCHEMBL15440706

CN(C)CCn1nc2c3c(c(NCc4ccccc4)ccc3c1=O)C(=O)c1ccccc1-2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.46
▸ POLB P06746 3/20 0.46
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ RAB9A P51151 2/20 0.46
▸ NPC1 O15118 1/20 0.46
▸ MITF O75030 1/20 0.46
▸ DNMT1 P26358 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ RAD52 P43351 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ UHRF1 Q96T88 1/20 0.46
▸ PLK1 P53350 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ HRH1 P35367 1/20 0.39
▸ ADRA1B P35368 1/20 0.39
▸ MEN1 O00255 3/20 0.38
▸ MAPT P10636 3/20 0.38
▸ LMNA P02545 2/20 0.38
▸ THRB P10828 2/20 0.38
▸ BLM P54132 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15449640 0.87 POLB (0.49) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL15440739 0.87 RAB9A (0.50) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL13468463 0.86 SMN1; SMN2 (0.46) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL13468116 0.86 SMN1; SMN2 (0.46) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL15440705 0.85 POLB (0.57) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL15440528 0.85 SMN1; SMN2 (0.45) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL15440679 0.85 POLB (0.47) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL15440469 0.83 SMN1; SMN2 (0.47) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL15440713 0.83 EHMT2 (0.45) KMT2APOLBL3MBTL1RAB9ANPC1
SCHEMBL13281984 0.82 SMN1; SMN2 (0.42) KMT2APOLBL3MBTL1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096536-B2 Asymmetrically substituted anthrapyridazone derivatives as cytostatics BS-154 S.P. ZO.O. (PL) 2015-08-04 — — US claimed
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS BS-154 SP. Z O.O. (PL) 2014-01-30 — — US claimed
US-9096536-B2 Asymmetrically substituted anthrapyridazone derivatives as cytostatics BS-154 S.P. ZO.O. (PL) 2015-08-04 — — US disclosed
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS BS-154 SP. Z O.O. (PL) 2014-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031357-A1 ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS ABCC1, ABCC3, ABCB1 KMT2A 4051/4885POLB 1452/4885L3MBTL1 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback